Adjuvant paclitaxel and trastuzumab for node-negative HER2- positive breast cancer
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
No Description Available
Description
No Description Available
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: Female
Updated on
20 Nov 2022.
Study ID: 1010002438 (0802-11)